What is first-line pharmacotherapy for most adults with type 2 diabetes?

Study for the Health CBE Exam. Prepare with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

What is first-line pharmacotherapy for most adults with type 2 diabetes?

Metformin is chosen as the first-line drug for most adults with type 2 diabetes because it lowers glucose effectively while carrying a low risk of hypoglycemia, tends to be weight neutral or even slightly weight-reducing, and is inexpensive with a strong safety and efficacy profile. It works mainly by suppressing hepatic glucose production and improving insulin sensitivity, effects that help reduce fasting and postprandial glucose levels. It also has potential cardiovascular and metabolic benefits beyond glycemic control, which reinforces its use as initial therapy. Insulin is not the default starting option because it requires injections, can cause hypoglycemia and weight gain, and is typically reserved for people with more advanced disease or those who do not achieve control with oral agents. Sulfonylureas increase insulin secretion and can lower glucose, but they carry a higher risk of hypoglycemia and weight gain compared with metformin, making them less ideal as first-line in most patients. GLP-1 receptor agonists are effective and can have cardiovascular or weight loss advantages, but they are injectable, more costly, and often have more gastrointestinal side effects; they are generally considered after metformin in the treatment sequence or in specific patient scenarios.

Metformin is chosen as the first-line drug for most adults with type 2 diabetes because it lowers glucose effectively while carrying a low risk of hypoglycemia, tends to be weight neutral or even slightly weight-reducing, and is inexpensive with a strong safety and efficacy profile. It works mainly by suppressing hepatic glucose production and improving insulin sensitivity, effects that help reduce fasting and postprandial glucose levels. It also has potential cardiovascular and metabolic benefits beyond glycemic control, which reinforces its use as initial therapy.

Insulin is not the default starting option because it requires injections, can cause hypoglycemia and weight gain, and is typically reserved for people with more advanced disease or those who do not achieve control with oral agents.

Sulfonylureas increase insulin secretion and can lower glucose, but they carry a higher risk of hypoglycemia and weight gain compared with metformin, making them less ideal as first-line in most patients.

GLP-1 receptor agonists are effective and can have cardiovascular or weight loss advantages, but they are injectable, more costly, and often have more gastrointestinal side effects; they are generally considered after metformin in the treatment sequence or in specific patient scenarios.

More practice questions